# A Single Dose Study to Determine the Excretion, Balance and Metabolic Disposition of Radiolabelled GW642444.

> **NCT01286831** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 6 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** [14C]GW642444

## Key facts

- **NCT ID:** NCT01286831
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05-18
- **Primary completion:** 2010-07-09
- **Final completion:** 2010-07-09
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2017-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01286831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01286831, "A Single Dose Study to Determine the Excretion, Balance and Metabolic Disposition of Radiolabelled GW642444.". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01286831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*